We have blazed new trails in pursuit of a cure
For the last 20 years, the MMRF has transformed myeloma research and the entire cancer research system. Every new initiative we drive builds upon our previous successes. From our founding, we have looked to disrupt the future as we make an impact now.
The MMRF was founded1998
Patient-founded and rooted in business principlesFirst myeloma scientists
We brought the first 350 researchers to the fieldFirst tissue bank2000
Researchers needed patient tissue — so we built the first multi-center tissue bank in myeloma with over 4K tissue samples.Myeloma-focused clinical trials
We built the MMRC and opened 80+ clinical trials with thousands of myeloma patients.Groundbreaking genome sequencing
The tissue bank allowed us to sequence the myeloma genome for the first time.Largest genomic landscape 2010
Our partnership with 76 clinical sites worldwide allowed us to develop the largest comprehensive genomic landscape for myeloma patients through our CoMMpass StudyMyeloma subtypes: every patient is unique
We discovered that multiple myeloma is not one disease — it has many subtypes.First platform trial in myeloma
We launched the MMRF MyDRUG study to bring treatments to each of those subtypes.Pioneering venture philanthropy
Then we created the Myeloma Investment Fund (MIF) — the first collaborative network of experts dedicated to developing promising new therapies for myeloma patients.First at-home genomic testing 2020
We launched the MMRF CureCloud®, a first-of-its-kind patient-focused genomic research study, so that data from the genomic, clinical, and immune landscapes can combine to be even more powerful.- With decades of experience and constant innovation, we are on the path to curing multiple myeloma.